Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal first-quarter loss Monday on higher research and development costs. The company lost $23.5 million, compared with a loss of $13.9 million the same quarter a year prior.
GlaxoSmithKline PLC said it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.
Beckman Coulter, Inc. announced that it has entered into a definitive merger agreement under which Danaher will acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash.
Abbott has introduced the PLEX-ID Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens. This assay enables rapid and accurate detection of potentially dangerous microorganisms.
Wilden, a leader in air-operated double-diaphragm pump technology, will be introducing its new Full Stroke PTFE Diaphragms for use on all of its AODD pump lines at INTERPHEX 2011.
Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy.
An international team of researchers has made new links between 29 regions of the genome and ulcerative colitis. The new findings increase the total number of genome regions known to be associated with inflammatory bowel disease to 99.
Acacia Pharma announces it has completed a Phase 1 clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the new use of treatment of dry mouth in advanced cancer patients.
Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.
Pfizer Inc. said it will expand its European business by acquiring Ferrosan's consumer health care business which includes vitamins and skincare products. The New York drugmaker did not disclose financial terms of the deal.
Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
Dutch biotechnology company Crucell NV said it had a net loss in the fourth quarter because of lower sales of its top selling vaccine, Quinvaxem, along with less demand for flu vaccines.
The boards of Sanofi-Aventis SA and Genzyme Corp. were scheduled to meet Sunday to discuss a deal between the two companies, but talks could continue throughout the week before a deal is finalized, according to a published report.
Almac’s new 240,000 sq. ft. North American Headquarters, north of Philadelphia is part of the Almac Group’s integrated services solutions strategy. The facility delivers full-service, integrated solutions to pharmaceutical and biotech clients.
Clavis Pharma, a Norwegian cancer drug development company, announces that its partner, Clovis Oncology, Inc., has recruited the first patient into a Phase 2 clinical study with CP-4126 (also known as CO-101).